The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
Open accessAbstract
BACKGROUND: Cryptococcal meningitis associated with human immunodeficiency virus (HIV) infection causes more than 600,000 deaths each year worldwide. Treatment has changed little in 20 years, and there are no imminent new anticryptococcal agents. The use of adjuvant glucocorticoids reduces mortality among patients with other forms of meningitis in some populations, but their use is untested in patients with cryptococcal meningitis. METHODS: In this double-blind, randomized, placebo-controlled trial, we recruited adult patients with HIV-associated cryptococcal meningitis in Vietnam, Thailand, Indonesia, Laos, Uganda, and Malawi. All the patients received either dexamethasone or placebo for 6 weeks, along with combination antifungal therapy with amphotericin B and fluconazole. RESULTS: The trial was stopped for safety reasons after the enrollment of 451 patients. Mortality was 47% in the dexamethasone group and 41% in the placebo group by 10 weeks (hazard ratio in the dexamethasone group, 1.11; 95% confidence interval [CI], 0.84 to 1.47; P=0.45) and 57% and 49%, respectively, by 6 months (hazard ratio, 1.18; 95% CI, 0.91 to 1.53; P=0.20). The percentage of patients with disability at 10 weeks was higher in the dexamethasone group than in the placebo group, with 13% versus 25% having a prespecified good outcome (odds ratio, 0.42; 95% CI, 0.25 to 0.69; P<0.001). Clinical adverse events were more common in the dexamethasone group than in the placebo group (667 vs. 494 events, P=0.01), with more patients in the dexamethasone group having grade 3 or 4 infection (48 vs. 25 patients, P=0.003), renal events (22 vs. 7, P=0.004), and cardiac events (8 vs. 0, P=0.004). Fungal clearance in cerebrospinal fluid was slower in the dexamethasone group. Results were consistent across Asian and African sites. CONCLUSIONS: Dexamethasone did not reduce mortality among patients with HIV-associated cryptococcal meningitis and was associated with more adverse events and disability than was placebo. (Funded by the United Kingdom Department for International Development and others through the Joint Global Health Trials program; Current Controlled Trials number, ISRCTN59144167.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Park, B. J., Wannemuehler, K. A., Marston, B. J., Govender, N., Pappas, P. G., & Chiller, T. M. (2009) · AIDS · doi:10.1097/qad.0b013e328322ffac · Cited by 2,014
Dexamethasone in Adults with Bacterial Meningitis
de Gans, J., & van de Beek, D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021334 · Cited by 1,205
Dexamethasone for the Treatment of Tuberculous Meningitis in Adolescents and Adults
Thwaites, G. E., Bang, N. D., Dung, N. H., Quy, H. T., Oanh, D. T. T., Thoa, N. T. C., Hien, N. Q., Thuc, N. T., Hai, N. N., Lan, N. T. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040573 · Cited by 1,043
Self-citationTreatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome
van der Horst, C. M., Saag, M. S., Cloud, G. A., Hamill, R. J., Graybill, J. R., Sobel, J. D., Johnson, P. C., Tuazon, C. U., Kerkering, T., Moskovitz, B. L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707033370103 · Cited by 820
Baber, N. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05705.x · Cited by 759
Dexamethasone for treatment of tuberculous meningitis in adolescents and adults
Tunkel, A. R. (2005) · Current Infectious Disease Reports · doi:10.1007/s11908-005-0059-0 · Cited by 671
Casadevall, A., & Perfect, J. R. (1998) · ASM Press eBooks · doi:10.1128/9781555818241 · Cited by 661
Glucocorticoids and the Th1/Th2 Balance
ELENKOV, I. J. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1321.010 · Cited by 612
Cited by
Limper, A. H., Adenis, A., Le, T., & Harrison, T. S. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30303-1 · Cited by 472
Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy
Williamson, P. R., Jarvis, J. N., Panackal, A. A., Fisher, M. C., Molloy, S. F., Loyse, A., & Harrison, T. S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.167 · Cited by 480
Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa
Molloy, S. F., Kanyama, C., Heyderman, R. S., Loyse, A., Kouanfack, C., Chanda, D., Mfinanga, S., Temfack, E., Lakhi, S., Lesikari, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710922 · Cited by 396
Self-citationChang, C. C., Harrison, T. S., Bicanic, T. A., Chayakulkeeree, M., Sorrell, T. C., Warris, A., Hagen, F., Spec, A., Oladele, R., Govender, N. P., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00731-4 · Cited by 326
Self-citationSingle-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
Jarvis, J. N., Lawrence, D. S., Meya, D. B., Kagimu, E., Kasibante, J., Mpoza, E., Rutakingirwa, M. K., Ssebambulidde, K., Tugume, L., Rhein, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2111904 · Cited by 286
Self-citationIndex-TB Guidelines: Guidelines on extrapulmonary tuberculosis for India
Sharma, S. K., Ryan, H., Khaparde, S., Sachdeva, K. S., Singh, A. D., Mohan, A., Sarin, R., Paramasivan, C. N., Kumar, P., Nischal, N., et al. (2017) · Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1950_16 · Cited by 279
Analysis and reporting of adverse events in randomised controlled trials: a review
Phillips, R., Hazell, L., Sauzet, O., & Cornelius, V. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024537 · Cited by 228
Epidemiology of meningitis and encephalitis in the United States, 2011–2014
Hasbun, R., Rosenthal, N., Balada-Llasat, J. M., Chung, J., Duff, S., Bozzette, S., Zimmer, L., & Ginocchio, C. C. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix319 · Cited by 171
Cerebrovascular injury in cryptococcal meningitis
Mishra, A. K., Arvind, V. H., Muliyil, D., Kuriakose, C. K., George, A. A., Karuppusami, R., Benton Carey, R. A., Mani, S., & Hansdak, S. G. (2018) · International Journal of Stroke · doi:10.1177/1747493017706240 · Cited by 82
Jarvis, J. N., Leeme, T. B., Molefi, M., Chofle, A. A., Bidwell, G., Tsholo, K., Tlhako, N., Mawoko, N., Patel, R. K. K., Tenforde, M. W., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy515 · Cited by 86
Ngan, N. T. T., Mai, N. T. H., Tung, N. L. N., Lan, N. P. H., Tai, L. T. H., Phu, N. H., Chau, N. V. V., Binh, T. Q., Hung, L. Q., Beardsley, J., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15010.1 · Cited by 28
Self-citationTocilizumab Induces IL-10-Mediated Immune Tolerance in Invasive Candidiasis
Tan, Z., Mok, M. M. H., Mar Soe, W., Thamboo, T. P., Goh, J. G., Sam, Q. H., Osato, M., Ravikumar, S., & Chai, L. Y. A. (2021) · Journal of Fungi · doi:10.3390/jof7080656 · Cited by 6
Metadata
- Authors
- Beardsley, J., Wolbers, M., Kibengo, F. M., Ggayi, A.-B. M., Kamali, A., Cuc, N. T. K., Binh, T. Q., Chau, N. V. V., Farrar, J., Merson, L., Phuong, L., Thwaites, G., Van Kinh, N., Thuy, P. T., Chierakul, W., Siriboon, S., Thiansukhon, E., Onsanit, S., Supphamongkholchaikul, W., Chan, A. K., Heyderman, R., Mwinjiwa, E., van Oosterhout, J. J., Imran, D., Basri, H., Mayxay, M., Dance, D., Phimmasone, P., Rattanavong, S., Lalloo, D. G., & Day, J. N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-02-11
- Volume
- 374
- Issue
- 6
- Pages
- 542-554
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2277731646
- Cited by
- 315
- References
- 29
- FWCI
- 37.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.